Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 6:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 5,852 matching trials from the live ClinicalTrials.gov search.
Filters: "gene therapy" Clear all
Completed Phase 3 Interventional

Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

NCT00336791
View directory record Official record
Conditions
Breast Cancer
Interventions
5-Fluorouracil, Cyclophosphamide, Doxorubicin, Paclitaxel, Epirubicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 15, 2026, 6:46 PM EDT
Suspended Phase 2 Interventional

ARN-75039 Lassa Fever Treatment in West Africa

NCT07419373
View directory record Official record
Conditions
Lassa Fever
Interventions
ARN-75039 high, Intravenous ribavirin, ARN-75039 low
Drug
Lead sponsor
Arisan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 15, 2026, 6:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

NCT06185673
View directory record Official record
Conditions
Oculopharyngeal Muscular Dystrophy
Interventions
BB-301: Dose escalation phase 1b cohort 1, BB-301: Dose escalation phase 1b cohort 2, BB-301: Dose escalation phase 1b cohort 3, BB-301: Dose expansion phase 2a
Genetic
Lead sponsor
Benitec Biopharma, Inc.
Industry
Eligibility
Up to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2040
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 15, 2026, 6:46 PM EDT
Recruiting No phase listed Observational

Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

NCT01257269
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura, Familial Thrombotic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Congenital, Upshaw-Schulman Syndrome
Interventions
Observation
Other
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Other
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2030
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 15, 2026, 6:46 PM EDT
Active, not recruiting Phase 2 Interventional

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

NCT04334941
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Talazoparib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
561
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 362 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 15, 2026, 6:46 PM EDT
Completed Phase 1 Interventional

Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients

NCT01802970
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Anakinra plus Standard of Care
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 15, 2026, 6:46 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Ivermectin and Human Immunity

NCT03459794
View directory record Official record
Conditions
Ivermectin
Interventions
Ivermectin, Placebo
Drug · Other
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 15, 2026, 6:46 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms

NCT03348670
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone - Usual, Abiraterone - Study
Drug
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Industry
Eligibility
22 Years to 75 Years · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 15, 2026, 6:46 PM EDT
Completed Phase 1 Interventional

A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing

NCT00381173
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Prostate Cancer, Colon Cancer, Renal Cancer
Interventions
Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 15, 2026, 6:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS

NCT00617383
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
10 Years to 45 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 15, 2026, 6:46 PM EDT
Completed Not applicable Interventional

Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma

NCT00590941
View directory record Official record
Conditions
Lymphoma, Diffuse Large Cell
Interventions
Blood draw
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 15, 2026, 6:46 PM EDT
Completed No phase listed Observational

Collection of Blood, Urine, and Stool to Monitor MetastaticColorectal Cancers

NCT03563651
View directory record Official record
Conditions
Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis, Questionnaire Administration
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 15, 2026, 6:46 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

NCT02931539
View directory record Official record
Conditions
Cytomegalovirus (CMV)
Interventions
Maribavir, Ganciclovir, Valganciclovir, Foscarnet, Cidofovir
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 15, 2026, 6:46 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

NCT02785939
View directory record Official record
Conditions
CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification, CDK4 Gene Amplification, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Docetaxel, Laboratory Biomarker Analysis, Palbociclib
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1065
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 659 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 15, 2026, 6:46 PM EDT
Completed Phase 2 Interventional

Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

NCT00312975
View directory record Official record
Conditions
Carcinoma, Non-small-cell Lung
Interventions
CP-675,206, best supportive care
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
14
States / cities
Bentonville, Arkansas • Fayetteville, Arkansas • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 15, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Choline Dehydrogenase and Sperm Function: Effects of Betaine

NCT02122211
View directory record Official record
Conditions
Men Carrying 2 Minor Alleles for Choline Dehydrogenase rs12676, Male Infertility
Interventions
Betaine supplement
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Oct 15, 2026, 6:46 PM EDT
Recruiting Phase 2 Interventional

ATEMPT 2.0: Adjuvant T-DM1 vs TH

NCT04893109
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer
Interventions
trastuzumab-emtansine, Trastuzumab SC, Paclitaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
53
States / cities
San Francisco, California • Derby, Connecticut • Fairfield, Connecticut + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 15, 2026, 6:46 PM EDT
Terminated Early Phase 1 Interventional Results available

Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas

NCT01783054
View directory record Official record
Conditions
Adenocarcinoma Pancreas
Interventions
Surgery, Genetic Expression, Chemotherapy
Procedure · Genetic · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Oct 15, 2026, 6:46 PM EDT
Completed No phase listed Observational

Biomarker Database Registry for Photodynamic Therapy

NCT03319251
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 15, 2026, 6:46 PM EDT
Completed Not applicable Interventional Results available

Study of Cellutome System for Treatment of Individual Lesions in EB Pts

NCT02670837
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
Cellutome Epidermal Harvesting System
Device
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 15, 2026, 6:46 PM EDT
Completed Phase 2 Interventional Results available

Studies of Elevated Parathyroid Activity

NCT00001277
View directory record Official record
Conditions
Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm, Multiple Endocrine Neoplasia, MEN1
Interventions
68Ga-Dotatate, 18F-DOPA
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Months and older
Enrollment
1,553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 15, 2026, 6:46 PM EDT
Terminated Phase 2 Interventional Results available

Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure

NCT00555477
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 15, 2026, 6:46 PM EDT
Completed Phase 2 Interventional Results available

First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00308750
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
enzastaurin, pemetrexed, docetaxel, carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Burlington, North Carolina • Chapel Hill, North Carolina • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 15, 2026, 6:46 PM EDT